Coordination and Support Action · Finished
Kyron.bio WomenTech Cell line engineering for imporved fertility treatment
- Coordinator
- Kyron.bio, France
- Runs
- 1 July 2023 to 31 January 2024
- Status
- Finished
- EU funding
- €75k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101114052
What the project is doing
In the project's own words, from its summary on CORDIS.
kyron.bio is a female led biotech company on a mission is to unclog bottlenecks in therapeutic protein production, allowing better drugs to reach patients. We are using synthetic biology to engineer mammalian cell lines for improved bioproduction, harnessing highly efficient enzymes from diverse life forms. Our preliminary data demonstrates a 3X yield gain for the amount of therapeutic produced in our system, with further gains in yield, activity and stability predicted post optimisation
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Kyron.bio | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI